Imatinib plasma trough levels in chronic myeloid leukaemia: Results of a multicentre study CSTI571AIL11TGLIVEC

Hematological Oncology

Volumn 30, Issue 4, 2012, Pages 200-205

  Koren Michowitz, Maya ^a   Volchek, Yulia ^a   Naparstek, Elizabeth ^b   Gavish, Israel ^c   Levi, Itai ^d   Rowe, Jacob M ^e   Shimoni, Avichai ^a   Nagler, Arnon ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c HAEMEK MEDICAL CENTER   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^e RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Adherence; Chronic myeloid leukaemia; Imatinib

Indexed keywords

IMATINIB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; SELF REPORT; STEADY STATE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLAST CRISIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY; LEUKEMIA, MYELOID, CHRONIC-PHASE; LIVER; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PIPERAZINES; PROGNOSIS; PYRIMIDINES; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84870931711     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2005     Document Type: Article

References (22)

1. O'Brien SG, Guilhot F, Goldman JM, et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 2008; 112(11): 76[abstract 186].
2. Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009; 114(22): 462[abstract 1126].
3. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of european LeukemiaNet. J Clin Oncol 2009; 27(35): 6041-6051.
4. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293(5531): 876-880.
5. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28: 2381-2388.
6. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22(5): 935-942.
7. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352(21): 2211-2221.
8. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44(9): 879-94.
9. Dulucq S, Bouchet S, Turcq B, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008; 112(5): 2024-2027.
10. White DL, Dang P, Engler J, et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010; 28(16): 2761-2767.
11. White DL, Saunders VA, Dang P. CML patients with low OCT-1 activity achieve better molecular responses on high dose imatinib than on standard dose. those with high OCT-1 activity have excellent responses on either dose: a TOPS correlative study. Blood 2008; 112(11): 1093-1094[abstract 3187].
12. White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006; 108(2): 697-704.
13. Haouala A, Widmer N, Duchosal MA, et al. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 2011; 117(8): e75-87.
14. Beumer JH, Natale JJ, Lagattuta TF, et al. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome. Pharmacotherapy 2006; 26(7): 903-907.
15. Larson RA, Druker BJ, Guilhot FA, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111(8): 4022-4028.
16. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109(8): 3496-3499.
17. Blasdel C, Wang Y, Lagattuta T, et al. Therapeutic drug monitoring of imatinib and impact on clinical decision making. Blood 2006; 108(11): 290b[abstract 4820].
18. Parise RA, Ramanathan RK, Hayes MJ, et al. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2003; 791(1-2): 39-44.
19. White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007; 110(12): 4064-4072.
20. Thomas J, Wang L, Clark RE, et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104(12): 3739-3745.
21. Baccarani M, Druker BJ, Cortes-Franco J, et al. 24months update of the TOPS study: a phase III, randomized, open-label study of 400mg/d (SD-IM) versus 800mg/d (HD-IM) of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP). Blood 2009; 114(22): 142[abstract 337].
22. Hiwase DK, Saunders V, Hewett D, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 2008; 14(12): 3881-3888.